Sun Pharma gets USFDA approval for acne drug
Sun Pharma has received approval for its new drug application for acne treatment from the USFDA recently, and is now in strong position to strengthen its portfolioDrug major Sun Pharma has recently received an approval for its drug application for a new acne treatment drug- XiminoTM extended-release capsules from US Food and Drug Administration (USFDA). This development will help the...
Login or Register to read the full article
Sun Pharma has received approval for its new drug application for acne treatment from the USFDA recently, and is now in strong position to strengthen its portfolio
Drug major Sun Pharma has recently received an approval for its drug application for a new acne treatment drug- XiminoTM extended-release capsules from US Food and Drug Administration (USFDA). This development will help the company strengthen its position in the US, with more drug supply in the dermatology treatment.
The application for XiminoTM (Minocycline HCl) extended-release capsules has been approved by USFDA in the strengths of 45 mg, 90 mg and 135 mg, Sun Pharma said in a statement.
XiminoTM extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
"This approval further strengthens the company's branded dermatology portfolio in the US. It expects XiminoTM extended-release capsules to be available for patients during the fourth quarter of 2015," the Mumbai-based company said.
Drug major Sun Pharma has recently received an approval for its drug application for a new acne treatment drug- XiminoTM extended-release capsules from US Food and Drug Administration (USFDA). This development will help the company strengthen its position in the US, with more drug supply in the dermatology treatment.
The application for XiminoTM (Minocycline HCl) extended-release capsules has been approved by USFDA in the strengths of 45 mg, 90 mg and 135 mg, Sun Pharma said in a statement.
XiminoTM extended-release capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
"This approval further strengthens the company's branded dermatology portfolio in the US. It expects XiminoTM extended-release capsules to be available for patients during the fourth quarter of 2015," the Mumbai-based company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd